Directing research, development, and regulatory affairs at Cardea, Dr. Barron earned her PhD in Cell Biology, Stem Cells, and Development at the University of Colorado Denver Anschutz Medical Campus. Dr. Barron brings 21 years of a rich and diverse research background in academic, pharmaceutical, and regulatory settings to her role optimizing biological systems and directing regulatory strategies for clinical products. After obtaining her BS in Biochemistry/Cell Biology at the University of California, San Diego, Dr. Barron managed a lab at the Ludwig Institute for Cancer Research, where she designed and produced over 50 novel antibodies for C. elegans targets, optimizing them for in vivo and in vitro assays. Her doctorate work led to the elucidation of a novel signaling pathway that could be linked to craniofacial defects in pediatric patients. As a postdoc at Stanford, Dr. Barron was awarded a NIH training grant to develop a new in vitro drug screening platform to assess cardiac safety of novel compounds on iPSC-derived human cardiomyocytes. While at Nanomedical, Dr. Barron wrote several peer-reviewed publications and white papers to support technology and product development, and she was awarded a DARPA grant to develop therapeutic drug monitoring at the hospital bedside. Her leadership has led to multiple successful product launches and novel nanotechnology-enabled applications that opened broader customer markets. With her role in Cardea, Dr. Barron drives the Internet of Biology movement by shaping new strategic alliances with pharma and academic partners to integrate graphene field effect transistors into new products. With a proven track record and a deep understanding of biology and its application to life science and clinical markets, Dr. Barron is uniquely equipped to guide successful research and development projects towards commercial success.